Since 2021, the story of GLP-1s has illustrated that scientific progress is rarely a straight line from hypothesis to patient ...
A November 2025 Kaiser Family Foundation poll found that 1 in 8 U.S. adults have tried a GLP-1 medication for weight loss, diabetes or another condition. And we expect that number to rise now that one ...
Who controls the narrative, where the money is going, and why patients need to be at the centre of what comes next News headlines, on your Instagram feed, song lyrics, in day-to-day conversation; few ...
The FDA requested that manufacturers of GLP-1 receptor agonists remove information regarding risks of suicidal behavior and ideation from drug labels following a detailed review of existing data, the ...
Soaring in popularity, GLP-1 medications—from weekly injections to newly available pills—are rapidly reshaping how Americans ...
Phenomix's MyPhenome test continues to demonstrate predictive accuracy in identifying which patients are most likely to respond to GLP-1 therapies such as semaglutide. Studies presented at Obesity ...
A new umbrella review reveals how GLP-1 therapies shape cardiovascular, renal, and metabolic outcomes in type 2 diabetes while highlighting drug-specific advantages and the need to manage ...
Medications for obesity may improve fertility, but there are many unknowns when it comes to using them during pregnancy.
At a White House event Thursday, President Trump announced deals with drugmakers Novo Nordisk and Eli Lilly to offer their popular GLP-1 obesity and diabetes drugs at lower prices for some Americans, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results